ImmunoGen and Lilly unite to develop cancer treatments

12/20/2011 | Wall Street Journal, The

ImmunoGen and Eli Lilly and Co. agreed to jointly develop antibody-based cancer drugs in a deal worth at least $20 million. The agreement gives Lilly exclusive licensing rights to some of ImmunoGen's cancer drugs in exchange for a $200 million milestone fee for each drug licensed as well as royalties on any product developed through the partnership. Maytansinoid targeted antibody payload technology developed by ImmunoGen delivers drugs straight to cancer cells.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA